Sign In
Buy ATRS
$5.59
+0 (+0%)
At Close: Jul 20, 2022
Antares Pharma, Inc. Just Released Its Full-Year Earnings: Here’s What Analysts Think
10:14am, Thursday, 05'th Mar 2020
It's been a pretty great week for Antares Pharma, Inc. (NASDAQ:ATRS) shareholders, with its shares surging 13% to...
Antares Pharma (NASDAQ:ATRS) Trading 8.7% Higher on Analyst Upgrade
06:49am, Thursday, 05'th Mar 2020
Antares Pharma Inc (NASDAQ:ATRS) shares traded up 8.7% on Wednesday after Raymond James raised their price target on the stock from $5.65 to $6.00. Raymond James currently has a strong-buy rating on t
Stargazing in March: Snow-white Pluto and the eight dwarfs
01:24pm, Wednesday, 04'th Mar 2020
Celebrate 90 years since the planet was discovered with a rare chance to glimpse one of the iciest places in the solar system
Analysts Are Bullish on These Healthcare Stocks: Antares Pharma (ATRS), Durect (DRRX)
12:29pm, Wednesday, 04'th Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antares Pharma (ATRS) and Durect (DRRX) with bullish
Analysts Are Bullish on These Healthcare Stocks: Antares Pharma (ATRS), Durect (DRRX)
12:29pm, Wednesday, 04'th Mar 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antares Pharma (
ATRS
–
Research Report
) and Durect (
DRRX
–
Research Report
) with bullish sentim
122,622 Shares in Antares Pharma Inc (NASDAQ:ATRS) Acquired by Advisory Research Inc.
09:20am, Wednesday, 04'th Mar 2020
Advisory Research Inc. purchased a new position in shares of Antares Pharma Inc (NASDAQ:ATRS) in the 4th quarter, Holdings Channel reports. The firm purchased 122,622 shares of the specialty pharmaceu
Antares Pharma Inc (ATRS) Q4 2019 Earnings Call Transcript
02:00am, Wednesday, 04'th Mar 2020
ATRS earnings call for the period ending December 31, 2019.
Raymond James Maintains Strong Buy on Antares Pharma, Raises Price Target to $6
12:00am, Wednesday, 04'th Mar 2020Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q4 2019 Results - Earnings Call Transcript
08:15pm, Tuesday, 03'rd Mar 2020
Antares Pharma, Inc. (NASDAQ:ATRS) Q4 2019 Results Earnings Conference Call March 03, 2020 08:30 AM ET Company Participants Jack Howarth - Vice President of Cor
How Antares Pharma Beat Expectations in Q4
08:00pm, Tuesday, 03'rd Mar 2020
Products from the pharmaceutical technology company continued to pick up momentum in the fourth quarter.
Antares Pharma Reports Q4 and Full Year 2019 Financial Results
02:02pm, Tuesday, 03'rd Mar 2020
Antares Pharma reported operating and financial results for the fourth quarter and full year ended December 31, 2019. The post Antares Pharma Reports Q4 and Full Year 2019 Financial Results appeared f
40 Healthcare Stocks Moving In Tuesday's Pre-Market Session
01:10pm, Tuesday, 03'rd Mar 2020
Gainers
Stealth BioTherapeutics, Inc. (NASDAQ: MITO) shares surged 74.2% to $3.31 during Tuesday's pre-market session. According to the most recent rating by H.C....
The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More
12:51pm, Tuesday, 03'rd Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) Forty Seven Inc (NASDAQ: FTSV )( announced a deal
Antares Pharma: 4Q Earnings Snapshot
12:22pm, Tuesday, 03'rd Mar 2020
EWING, N.J. (AP) _ Antares Pharma Inc. (ATRS) on Tuesday reported fourth-quarter profit of $4.7 million.
The Ewing, New Jersey-based company said it had profit of 3 cents per share.
The results surpas
Antares Pharma reaffirms FY20 revenue view $135M-$155M, consensus $147.56M ATRS
12:03pm, Tuesday, 03'rd Mar 2020
Antares Pharma reaffirms FY20 revenue view $135M-$155M, consensus $147.56M ATRS
